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http://dx.doi.org/10.1016/j.pedneo.2
1875-9572/Copyright ª 2015, TaiwanBackground: The direct antiglobulin test (DAT) is the cornerstone of the diagnosis of hemolytic
disease of the newborn (HDN). The aim of this study was to review the incidence and causes of
positive DAT in cord blood in relation to development of HDN.
Methods: We retrospectively reviewed all results of DAT, which is routinely performed in cord
blood samples, along with the laboratory and infants’ medical records.
Results: DAT was positive in 70/2695 (2.59%) cases. In 64/70 (91.43%) cases, DAT positivity was
attributed to ABO incompatibility. There were 50/218 (22.93%) DAT (þ) cases in the A/O group
and 13/97 (13.40%) cases in the B/O group (pZ 0.0664). Two DAT (þ) cases were attributed to
maternal alloimmunization (anti-Fya and anti-JKb, respectively), and one to maternal IgG au-
toantibodies that developed after methyldopa treatment. Among the 70 DAT (þ) cases, 30
(42.86%) cases required phototherapy with no difference between the A/O and B/O groups.
The duration of phototherapy in the B/O group was significantly longer than in the A/O group
(p Z 0.024). There was a trend of correlation of increasing strength of DAT positivity with
phototherapy need. No false positive DAT case was detected.
Conclusions: Although ABO incompatibility remains the main reason of DAT (þ), other causes
(e.g., alloimmunization, drugs) should also be explored. The relevant impact of DAT (þ) on
HDN development should be considered.
Copyright ª 2015, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.fusion Department, Aretaieion Hospital, Athens University Medical School, V. Sofias 76, 11528 Athens,
hoo.com (S. Valsami).
014.11.005
Pediatric Association. Published by Elsevier Taiwan LLC. All rights reserved.
Direct antiglobulin test in cord blood 2571. IntroductionThe direct antiglobulin test (DAT) is a screening test for
antibodies present in an individual’s red cells and is used to
diagnose autoimmune hemolytic anemias as well as the
hemolytic disease of the newborn (HDN).1 A positive DAT in
a newborn results from the transplacental transfer of IgG
antibodies, which are present in maternal serum and
directed against antigens on fetal and neonatal red blood
cells (RBCs). Such antibodies may cause destruction of ne-
onates’ RBCs and shorten their life span, leading to clinical
manifestations of HDN and various degrees of hyper-
bilirubinemia and anemia.1
The factors that can lead to a positive DAT in neonates
are mainly the ABO incompatibility between the newborn
and the mother, maternal alloimmunization, and very
seldom maternal autoimmune hemolytic anemia.1 ABO in-
compatibility with a positive DAT is considered a major risk
factor for the development of severe hyperbilirubinemia
and neurotoxicity.2,3 By contrast, some studies report that
the positive DAT has only a poor predictive value for severe
hyperbilirubinemia.4e8
This study aimed to explore in a cohort of newborns the
incidence of DAT positivity, evaluate its strength, identify
its causes, and examine its association with hyper-
bilirubinemia, need for phototherapy, and transfusion for
the newborns.
2. Methods
Following the guidelines of the Ethics Committee, at
admittance to the Aretaieion University Hospital, all par-
turients sign an informed consent for indispensable labo-
ratory tests to be performed, including ABO/Rhesus D group
and DAT in cord blood. In this respect, we retrospectively
reviewed all results of DAT, which was routinely performed
in cord blood samples of all infants born between January
2011 and December 2012.
During this period, a total of 2695 cord blood samples
were analyzed. From the Blood Bank records, the following
data were evaluated: DAT results, strength of DAT positiv-
ity, infant/maternal ABO and Rhesus D group, antibody
screening, and antibody identification in cases of maternal
alloimmunization. A retrospective review of the charts of
infants with a positive cord blood DAT was also performed.
The following characteristics were recorded: sex, gesta-
tional age, mode of delivery, relevant antenatal and de-
livery data, (maternal medical history) treatment with
phototherapy (duration), peak serum total bilirubin (STB),
and transfusion history. The bilirubin level was plotted to
the hour-specific bilirubin nomogram based on Bhutani
et al9 as referred by Schutzman et al.10 The risk zone on the
nomogram was characterized as follows: zone a, low risk:
<40th percentile; zone b, low-intermediate risk: 40e75th
percentile; zone c, high-intermediate risk: 76e95th
percentile; and zone d, high risk: >95th percentile. Photo-
therapy was implemented according to the guidelines of
the neonatal department, based on the 2004 American
Academy of Pediatrics along with the revised 2011 Amer-
ican Academy of Pediatrics criteria, for the management of
hyperbilirubinemia in newborns.2,11Cord blood was collected by puncturing the umbilical
vein with needle and a syringe to avoid Wharton’s jelly
contamination. DAT was carried out using an automated
method (BIOVUE INNOVA Ortho Clinical Diagnostics, High
Wycombe, UK) according to the manufacturer’s instructions
and was characterized as negative, weak (equal to 0.5þ),
1þ, 2þ, 3þ, and 4þ. Blood group typing was performed
using standard blood bank techniques (slide or tube test).
Statistical analysis was performed using the t test for
continuous data, and Fisher’s exact test or the chi-square
test for categorical data as appropriate. Data were
analyzed with the SPSS.16 software. A p value of 0.05 or
less was considered statistically significant.3. Results
Among the 2695 neonates born between January 2011 and
December 2012, 1074 (39.85%) neonates were of group A,
407 (15.10%) of group B, 1105 (41.00%) of group O, and 109
(4.04%) of group AB. ABO incompatibility between neonates
and mothers was found in 481 (17.85%) cases. Of these, 218
neonates of group A and 97 of group B were born to group O
mothers (A/O, 218; B/O, 97). The remaining ABO incom-
patible cases identified were B/A, 38 cases; AB/A, 48 cases;
A/B, 43 cases; and AB/B, 37 cases. The ABO neonatal/
maternal compatibility status could not be determined in
296 cases (208 neonatal group A, 11 neonatal group AB, and
77 neonatal group B), as the study was retrospective and
data matching mothers and infants of different surnames
was lacking. All the remaining 1918 (71.17%) cases were
considered ABO compatible (A/A, 537; A/AB, 68; AB/AB,
13; B/AB, 38; B/B, 157; O/A, 223; O/B, 111; O/O, 539; O/
unknown maternal ABO group, as stated above, 232).
DATwas found to be positive in 70/2695 (2.59%) cases. In
64/70 (91.43%) cases, DAT positivity was attributed to ABO
incompatibility. There were 50/218 (22.93%) DAT positive
cases in the A/O group, 13/97 (13.40%) in the B/O group,
and 1/38 (2.63%) in the B/A group. The incidence of DAT
positivity was higher (although it did not reach statistical
significance) in the A/O group as compared to the B/O
group (p Z 0.0664).
In two cases, DAT positivity was the result of maternal
alloimmunization. The first case of alloimmunization was a
mother para 1 (B RhD positive), compound heterozygote for
sickle cell anemia and beta thalassemia. She had a history
of alloimmunization with anti-Fya and anti-JKb owing to
past transfusions, of which only anti-Fya was still detect-
able. The titer of anti-Fya never exceeded 64 during
pregnancy. The neonate (B RhD positive), delivered by ce-
sarean section at 33 weeks of gestation, was Fya antigen
positive and had a DAT positive (1þ) result. The presence of
anti-Fya, as the cause of DAT positivity, was confirmed via
an elution test. The neonate did not suffer hemolysis and
was discharged on Day 7 in good health.
The second case of alloimmunization was a mother para
3 (A RhD positive) without history of past transfusions, who
uneventfully delivered a male infant. The neonate (O RhD
positive) had a strong positive DAT (4þ). An antenatal
antibody screening test of the mother was not available and
the one performed at labor was positive. The alloantibody
identified had anti-Jkb specificity. The neonate was Jkb
Table 1 Number of neonates in the low-risk zone (zone
a), the low-intermediate risk zone (zone b), the high-
intermediate risk zone (zone c), and the high risk zone
(zone d) of the nomogram in relation to the strength of DAT
positivity, and cases that met phototherapy criteria.
Risk zone
distribution
DAT positivity DAT
positive
cases (%)
Cases meeting
phototherapy
criteria (%)
0.5þ 1þ 2þ 3þ 4þ
a 6 18 8 1 0 33 (47.14) 0 (0)
b 1 3 2 1 1 8 (11.43) 5 (62.5)
c 1 6 5 0 0 12 (17.14) 11 (91.66)
d 1 6 6 2 0 15 (21.43) 14 (93.33)
No data* 0 0 2 0 0 2* (2.86) 3*
Total 9 33 23 4 1 70 (100) 30 (42.86)
* Three infants were transferred at birth to Referral Centers
as they presented severe congenital heart disease (2 cases: risk
zone distribution and phototherapy unknown) and severe
dermatological problems (1 case: risk zone distribution d,
phototherapy unknown).
Figure 1 Direct antiglobulin test (DAT) positivity (DAT 0.5þ,
1þ, 2þ, 3þ, 4þ) in relation to need for phototherapy.
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red cells confirmed the diagnosis of HDN due to anti-Jkb. It
was the only 4þ DAT case in our cohort. The neonate
developed hemolysis and jaundice and responded well to
phototherapy.
One additional DAT positive case was an A RhD negative
male infant born to an AB RhD positive mother with a his-
tory of methyldopa treatment, owing to hypertension. Both
the mother and the neonate had a DAT positive result (3þ),
and the eluate obtained in both cases revealed a nonspe-
cific reaction. The neonate developed hemolysis and
jaundice and responded well to phototherapy.
As for the remaining three DAT positive cases, in two
cases concerning neonates of group A, the ABO status of the
mother was not available, whereas in the other A/A case
DAT positivity could not be attributed to any kind of
alloimmunization because of missing data of the mother. No
case of HDN due to maternal anti-D alloimmunization was
identified in our study.
Among the 70 DAT positive cases, the strength of DAT
positivity was distributed as follows: 0.5þ, 9/70 (12.86%);
1þ, 33/70 (47.14%); 2þ, 23/70 (32.86%); 3þ, 4/70 (5.71%);
4þ, 1/70 (1.43%). The strength of DAT positivity in the A/O
and the B/O groups was similar. No case with DAT 4þ pos-
itivity was detected in the ABO incompatibility group.
Among the 70 DAT positive cases, applying all to neo-
nates with gestational age >36 weeks, 30 (42.86%) met the
criteria and received phototherapy treatment. Twenty-two
of 50 (44%) infants belonged to the A/O group and six of 13
(46.2%) belonged to the B/O group, with the difference not
being significant (p Z 1). However, the duration of photo-
therapy in the B/O group (mean  SD, 34.42  45.49 hours)
was significantly longer than in the A/O group (mean  SD,
14.56  19.34 hours; p Z 0.024). The two additional cases
that received phototherapy were the newborns with HDN
due to anti-JKb and to maternal autoantibodies as a result
of methyldopa treatment of the mother. None of these
cases required an exchange transfusion or intravenous
immunoglobulin.
Fifteen out of seventy (15/70, 21.43%) infants with a
positive DAT developed clinically significant jaundice with
an STB value > 95th percentile for hour of life (high-risk,
zone d). The two subgroups, A/O (11/50) and B/O (4/13),
did not differ in terms of development of hyper-
bilirubinemia (p Z 0.7191).
The strength of DAT positivity in relation to the risk zone
(according to STB percentile for hour of life) and cases that
met the phototherapy criteria are depicted in Table 1.
There was a trend of correlation of increasing DAT pos-
itivity strength with increasing need for phototherapy as
shown in Figure 1. Further analysis revealed a linear rela-
tion between the percentage of phototherapy-treated ne-
onates (PPTN) and the DAT positivity strength:
PPTNZ 0.19 þ DAT  0.20 (p < 0.05 both for intercept and
slope, and R2 Z 98.31%). There was also a trend of corre-
lation of increasing DAT positivity strength with increased
duration of phototherapy (mean values). The duration of
phototherapy (mean hours) was 11.89 hours in the 0.5þ DAT
group, 15.09 hours in the 1þ DAT group, 21.31 hours in the
2þ DAT group, 22.00 hours in the 3þ DAT group, and 33.00
hours in the 4þ DAT group. For those data, there was a
statistically significant relation between the duration ofphototherapy (mean hours) per neonate (DPPN) and DAT
positivity strength (p < 0.05 both for intercept and slope,
and R2 Z 93.04%), specifically DPPN Z 9.20 þ DAT  5.46.4. Discussion
In this study, we retrospectively analyzed all DAT results
routinely performed in cord blood samples of all infants
born at the Aretaieion Hospital and explored the reasons
that led to DAT positivity, as well as its impact on neonatal
outcome.
The ABO incompatibility between neonate and mother
was 17.85%, in accordance with previous reports.12 The
higher frequency of A/O versus B/O incompatibility was
also in accordance with the ABO group distribution in
Greece.13
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percentage similar to that (2.3%) reported by Dillon et al14
but lower than that (3.5%) of Hershel et al.15 Both studies
applied the same methodology as the current study.14,15 In
accordance with previous studies, the current one pre-
sented ABO incompatibility in 91.43% of positive DAT
cases,15 and the incidence of DAT positivity was slightly
higher in neonates of group A/O (22.93%) when compared
to group B/O (13.40%; p Z 0.0664).6,16
In our cohort, two cases of DAT positivity resulted from
alloimmunization of the mother: one B/B case was due to
anti-Fya and one O/A case was due to anti-JKb. The preva-
lence of anti-Fya alloantibody in pregnant women is very low
(ranging from 0.01% to 5.4%), and although the neonate in
our study did not suffer hemolysis, there is a potential to
cause significant fetal and newborn hemolysis.17 Most of the
few case reports of anti-Jkberelated HDN described in the
literature developed a mild clinical course, as in our case,
but rare cases with severe HDN have also been reported.18,19
One additional A/AB case was attributable to maternal
IgG autoantibodies that developed during pregnancy as a
result of methyldopa treatment. Methyldopa can lead to a
positive DAT in about 20% of treated patients, but autoim-
mune hemolytic anemia develops in only 2% of patients.20
However, IgG autoantibodies against RBCs can cross the
placenta and cause HDN. This case is, to our knowledge, the
second in the literature.21
In our study, no case of positive DAT was attributed to
anti-D passive or immune alloimmunization of the mother.
In the A/O group with a positive DAT, there were four cases
of Rhesus D positive infants born to Rhesus D negative
mothers. All four mothers had a negative screening test
result during pregnancy and at labor, and no history of
prenatal Rhesus immune globulin administration. Thus, DAT
positivity was attributed to ABO incompatibility, and this
was also confirmed by elution tests. It has been shown that
the introduction of routine antenatal Rhesus immune
globulin prophylaxis led to an increase of false positive DAT
results in cord blood samples that were poorly predictive of
subsequent hyperbilirubinemia.14,22
However, there were three DAT positive cases in which
DAT positivity could not be explained owing to a lack of
data regarding the mother. We do not regard these cases as
false positives but as true positive ones, where the cause of
DAT positivity could not be clarified. In our study, no false
positive DAT cases were detected.22,23 All weak positive
DAT cases (0.5þ) were attributed to ABO incompatibility
and had relevant clinical impact. Additionally, it is worth
mentioning that DAT accuracy could be constrained owing
to a degree of subjectivity in the observer’s judgment. The
use of fully automated microtube gel methods could over-
come such problems along with technical pitfalls that could
result in a false positive DAT.24
Fifteen of 70 (21.43%) neonates with a DAT-positive
result developed hyperbilirubinemia (as defined by STB
>95th percentile for hour of life) and 30/70 (42.86%) cases
met the criteria and were treated with phototherapy. This
is higher than the phototherapy incidence among DAT-
positive neonates reported by Schutzman et al10 (12.9%),
but similar to that reported by Kaplan et al25 (49.4%), and
may be attributed to variant phototherapy criteria in
neonatal units.The incidence and the severity of hyperbilirubinemia
between A/O and B/O subgroups differs among published
studies, with many investigators suggesting that clinical
severity of HDN does not differ in the two subgroups, and
others proposing that B/O infants are at increased risk for
HDN and in need of intense treatment. In our study, similar
proportions of A/O and B/O infants met the criteria and
received phototherapy or developed clinically significant
jaundice (STB >95th percentile for hour of life). However,
the duration of phototherapy (hours) received by neonates
in the B/O group was higher than in the A/O group
(p Z 0.024). This finding could possibly suggest a slight
difference in clinical severity of HDN in the B/O group, but
cannot definitively document that B/O heterospecific neo-
nates are at higher risk than their A/O counterparts.16,25e28
The role of DAT screening in predicting HDN has been
debated over the past years.6,8,29,30 The predictive value of
the DAT positivity was not assessed in this retrospective
study, because only the DAT positive cases were taken into
consideration. However, it was found that among the DAT
(þ) cases, a trend of increasing DAT positivity strength with
increasing need for phototherapy might exist as shown in
Figure 1. In addition, a similar trend of increasing DAT
positivity strength with increased duration of phototherapy
may also exist. The main limitation of this result is related
to the small number of cases encountered with 3þ and 4þ
DAT.
In conclusion, although several reports have proposed
that routine cord blood DAT testing is not necessary, ac-
cording to our current retrospective study, its impact on
the newborn cannot be overlooked. Nevertheless, DAT
testing cannot replace STB measurements early in life.
Furthermore, although ABO incompatibility accounts for
the majority of DAT positive cases, other causes should be
also considered. Maternal screening tests and a careful look
at the history of drug administration during pregnancy
could identify other important but rare causes of DAT
positivity, aiding maternal and neonatal management.
Finally, prospective studies including costebenefit ones
with defined end points would be helpful.
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